Drug Pricing
Drug pricing policy encompasses the legislative, regulatory, and market-based mechanisms by which the United States sets, negotiates, or constrains the prices that consumers, insurers, and government programs pay for prescription medications. It is a long-running policy area involving federal negotiating authority, patent protections, pharmacy benefit manager (PBM) oversight, and the balance between drug affordability and pharmaceutical innovation.
The United States pays significantly higher prices for prescription drugs than peer nations, with the cost burden falling heavily on patients, employers, and federal programs like Medicare and Medicaid. The Inflation Reduction Act of 2022 represented the most sweeping change to drug pricing law in two decades, for the first time authorizing Medicare to directly negotiate prices for high-cost drugs; its first negotiated prices for ten drugs took effect in January 2026. The issue remains fiercely contested between those who argue government intervention is necessary to end corporate price-gouging and those who warn that price controls threaten the innovation pipeline that produces new medicines.
Left perspective
Democrats and progressives argue that the U.S. pharmaceutical market is structurally broken: drug companies exploit patent protections, pay-for-delay settlements, and PBM arrangements to extract monopoly rents from patients and taxpayers, while profiting far more than R&D investment justifies. They champion expanding Medicare's IRA-granted negotiation authority to cover more drugs more quickly, extending negotiated prices to private insurers, and enacting international reference pricing to ensure Americans pay no more than comparable nations. Senate Finance Ranking Member Ron Wyden, Sen. Bernie Sanders, and Sen. Elizabeth Warren have been the most active voices demanding transparency on the Trump administration's MFN deals, arguing those voluntary agreements lack enforceable savings and amount to giveaways to Big Pharma. The left's core case is that government leverage over market power—as the largest drug purchaser in the world—is the only structural solution to price disparities that cause patients to ration or forgo medications.
Right perspective
Republicans and conservatives broadly oppose government-mandated price controls in the pharmaceutical sector, arguing that the market, competition, and patent reform—not federal price-setting—are the proper tools to lower drug costs. While no Republican voted for the IRA's negotiation program in 2022, the Trump administration has maintained the existing Medicare negotiation program while pursuing an alternative approach: voluntary Most-Favored-Nation pricing agreements with individual manufacturers, the TrumpRx direct-to-consumer platform, and tariff-linked incentives to bring drug prices in line with other nations' rates. The right's intellectual framework holds that the IRA-style 'negotiation' is a misnomer for coercive price controls—backed by an excise tax up to 1,900% of daily U.S. revenues—that will deter investment in future drug development, particularly for diseases with smaller patient populations. On patent reform, there is genuine Republican support for measures that curb anti-competitive patent thickets and product hopping, as exemplified by Sen. Chuck Grassley chairing a bipartisan Senate Judiciary Committee markup that advanced six reform bills by voice vote in 2025.